Furthermore, an analysis of several tumor types failed to show any difference in the rate of LOH in tumors expressing mutant p53 with DN capacity compared with those with p53 mutant proteins unable to tetramerize and so lacking DN function, or in the survival of patients harboring these tumors (Shahbandi and Jackson 2019). This evidence concerns the gene TP53 and neoplasm.